Skip to main content

COVID-19 Topic Center

HIV/AIDS News

News
In high-income countries, the median lifetime cost of managing human immunodeficiency virus (HIV) is an estimated $377,820, according to a study published online ahead of print in the journal AIDS.   The finding stems from a systematic review of 75 studies, of which 50 were from high-income, 22…
News
Adding ibalizumab to optimized background therapy appears cost-effective for adults with multidrug-resistant HIV-1 infection, according to a study published in PharmacoEconomics.  Conducted by researchers from RTI Health Solutions and Georgetown University, the analysis considered the cost-…
News
Studies evaluating costs and outcomes of interventions to control sexually transmitted infections (STIs) in young people are mostly of low quality with limited focus, according to a systematic review published online ahead of print in the journal Sexually Transmitted Infections.   UK researchers…
News
Payments for human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) medication in the United States totaled more than $2.08 billion in 2018, according to a Centers for Disease Control and Prevention study recently published in Annals of Internal Medicine.  To gain insight into PrEP…
News
Among nearly 1.9 million US patients covered by Medicare, Medicaid, or commercial insurance, half had multiple chronic conditions, according to a study published online in Frontiers in Public Health. HIV/AIDS was the costliest cluster, averaging $48,293 a year per patient.  The finding stems from…
News
Earlier this month, the US Department of Health and Human Services (HHS), in collaboration with the Health Resources and Services Administration (HRSA), announced $2.24 billion in Ryan White HIV/AIDS Program grants awarded to cities, counties, states, and local community-based organizations. "…
News
Payments for HIV preexposure prophylaxis (PrEP) drugs in the United States totaled more than $2.08 billion in 2018, according to a study published online in the Annals of Internal Medicine. Researchers investigated prescriptions for tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) for…
News
With the goal to end the HIV epidemic by 2030 in mind, researchers of a recent study conducted an analysis in which they found that a significant proportion of individuals that could benefit from preexposure prophylaxis (PrEP) were not receiving the medication, and those who did had drastically…
News
Addressing the high costs of antiretroviral therapy (ART) and preexposure prophylaxis (PrEP) are key to ending the HIV epidemic, stated researchers in a study published in JAMA Network Open. Chien-Wen Tseng, MD, MS, MPH, department of family medicine and community health, John A Burns School of…
News
Tenofovir alafenamide-emtricitabine (F/TAF) has proved to be a noninferior, potentially safer option than tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP), but researchers of a study published in Annals of Internal Medicine sought to examine its potential…
Back to Top